Abstract
Neuroblastoma has attracted the interest of oncologists and immunologists because it has a number of biological properties, which may provide some insight into the neoplastic process and the host’s antitumor defense mechanisms. These features which have recently been reviewed1, include an unusually high incidence of spontaneous regression. On the basis of autopsy studies of adrenal glands taken from infants dying from other causes, it has been calculated that the incidence of neuroblastoma in situ exceeds that of clinically diagnosed neuroblastoma by almost 100 fold. It has been postulated that some host control mechanism is responsible for this phenomenon. It is not yet clear whether this disparity is due to some sort of differentiative influence through which neuroblastomas can differentiate into benign ganglioneuromas; however, it has been recognized for several years that human neuroblastoma can display evidence of maturation when cultivated in vitro 2. Recently, Schubert et al.3 have shown that suitable modifications of culture conditions can revèrsibly alter the transplantable murine neuroblastoma from a typical neuroblast to a cell with neurite outgrowth resembling a more mature nerve cell. Whether there is an accompanying change in the malignant behavior of such cells is not known. Further studies in this system are urgently needed to determine whether induction of differentiation in a neoplastic cell might control the malignant process.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
HELLSTROM, K. E. and HELLSTROM, I.: Immunity to neuroblastomas and melanomas. Annu Rev Med, 23: 19. 1972.
MURRAY, M. R. and STOUT, A. P.: Distinctive characteristics of the sympathicoblastoma cultivated in vitro. A method for prompt diagnosis. Am J Pathol, 23: 429, 1947.
SCHUBERT, D., HUMPHREYS, S., deVITRY, F. and JACOB, F.: Induced differentiation of neuroblastoma. Dee Biol, 25: 514, 1971.
MARTIN, R. F. and BECKWITH, J. B.: Lymphoid infiltrates in neuroblastomas, their occurrence and prognostic significance. J Pediatr Surg, 3: 161, 1968.
BILL, A. H. and MORGAN, A.: Evidence for immune reactions to neuroblastoma and future possibilities for investigation. J Pediatr Surg, 5: 111, 1970.
NELSON, L., RAMOS. C. OETTGEN, H. and MURPHY, M.: DNCB reactivity in children with neuroblastoma. Proc Am Assoc Cancer Res, 12: 86, 1971.
SMITH. R. T.: Tumor specific immune mechanisms. New Engl J Med, 278: 1207, 1268, 1326. 1968.
HELLSTROM, K. E. and HELLSTROM, L. Immunological enhancement as studied by cell culture techniques. Annu Rev Microhiol, 24: 373, 1970.
SJOGREN, H. O. HELLSTROM, L. BANSAL, S. C. and HELLSTROM, K. E.: Suggestive evidence that the “blocking antibodies” of tumor-bearing individuals may be antigen-antibody complexes. Proc Nati Acad Sci. 68: 1372, 1971.
COHEN. A. M. BURDICK, J. F. and KETCHAM, A. S.: Tumor specific cellular immunity. J Surg Res, 11: 421, 1971.
HELLSTROM, I., HELLSTROM, K. E. BILL, A. H. PIERCE, G. E. and YANG, J. P. S.: Studies on cellular immunity to human neuroblastoma cells. Int J Cancer, 6: 172, 1970.
HELLSTROM, I., HELLSTROM, K. E., PIERCE, G. E. and BILL, A. H.: Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci, 60: 1231, 1968.
JAGARLAMOODY, S. M. AUST, J. C., TEW, R. H. and McKHANN, C. F.: In vitro detection of cytotoxic cellular immunity against tumor-specific antigens by a radioisotopic technique. Proc Natl Acad Sci, 68: 1346, 1971.
KUMAR, S., TAYLOR, G., STEWARD, J. K., WAGHE, M. A. and PEARSON, D.: Cellular immunity in Wilms’ tumor and neuroblastoma. Int J Cancer, 10: 36, 1972.
PRASAD, K. N., ZAMBERNARD, J., LASHER, R. and VANWOERT, M. H.: Transmission of mouse neuroblastoma by a cell-free extract. Nature, 228: 997, 1970.
LEWIS, M. G., IKONOPISOV, R. L., NAIRN, R. C., PHILLIPS, T. M., FAIRLEY, G. H., BODENHAM, D. C. and ALEXANDER, P.: Tumor-specific antibodies in human malignant melanoma and their relationship to the extent of disease. Br Med J, 3: 547, 1969.
O’TOOLE, C. PERLMANN, P.. ONSGAARD, B., MOBERGER, G. and EDSMYR, F.: Cellular immunity to human urinary bladder carcinoma. 1. Correlation to clinical stage and radiotherapy. Int J Cancer, 10: 77, 1972.
SJOGREN, H. O., HELLSTROM, I. BANSAL, S. C., WARNER, G. A. and HELLSTROM, K. E.: Elution of “blocking factors” from human tumors, capable of abrogating tumor cell destruction by specifically immune lymphocytes. Int J Cancer, 9: 274, 1972.
HELLSTROM, I.. HELLSTROM, K. E., SJOGREN, H. O. and WARNER, G. A.: Serum factors in tumor-free patients cancelling the blocking of cell-mediated tumor immunity. Int J Cancer, 8: 185, 1972.
TUMILOWICZ, J. J., NICHOLS, W. W., CHOLON, J. J. and GREENE, A. E.: Definition of a continuous human cell line derived from neuroblastoma. Cancer Res, 30: 2110, 1970.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1973 Ontario Cancer Treatment and Research Foundation
About this chapter
Cite this chapter
Dent, P.B. (1973). Immunological Aspects of Neuroblastoma. In: Godden, J.O. (eds) Cancer in Childhood. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-2070-8_24
Download citation
DOI: https://doi.org/10.1007/978-1-4684-2070-8_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-2072-2
Online ISBN: 978-1-4684-2070-8
eBook Packages: Springer Book Archive